Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10402623 | 0.80 | CES1 (0.45) | CES2CES1AKR1B1GAAALDH1A1 | |
| SCHEMBL10402622 | 0.80 | CES1 (0.45) | CES2CES1AKR1B1GAAALDH1A1 | |
| SCHEMBL5321145 | 0.77 | CYP3A4 (0.46) | CES2CES1AKR1B1GAAALDH1A1 | |
| SCHEMBL163579 | 0.76 | ALDH1A1 (0.55) | CES2CES1AKR1B1ALDH1A1MAPK1 | |
| Methyl Alcohol SCHEMBL4364856 | 0.73 | TSHR (0.53) | CES2CES1AKR1B1ALDH1A1MAPK1 | |
| SCHEMBL10535988 | 0.73 | CES1 (0.57) | CES2CES1AKR1B1ALDH1A1MAPK1 | |
| SCHEMBL7324968 | 0.72 | ALDH1A1 (0.45) | CES2CES1AKR1B1GAAALDH1A1 | |
| SCHEMBL7916718 | 0.72 | CES1 (0.45) | CES2CES1AKR1B1GAAALDH1A1 | |
| SCHEMBL3048337 | 0.71 | ALDH1A1 (0.59) | CES2CES1AKR1B1ALDH1A1MAPK1 | |
| Phenylacetic Acid SCHEMBL27442533 | 0.71 | AKR1B1 (0.59) | CES2CES1AKR1B1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361901-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | PHARMAKEA, INC. | 2020-11-19 | — | — | US | claimed |
| EP-3510023-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190202805-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | PHARMAKEA, INC. | 2019-07-04 | — | — | US | claimed |
| WO-2018048943-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| US-20200361901-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | PHARMAKEA, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10774069-B2 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | PHARMAKEA, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3510023-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190202805-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | PHARMAKEA, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018048943-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774069-B2 | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | LOXL2, LOXL1, LOX | CES2 440/4885CES1 181/4885AKR1B1 264/4885 |
| US-20190202805-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | LOXL2, LOXL1, LOX | CES2 440/4885CES1 181/4885AKR1B1 264/4885 |
| US-20200361901-A1 | CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING | LOXL2, LOXL1, LOX | CES2 440/4885CES1 181/4885AKR1B1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.